Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03121352

Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer

Metastatic Triple Negative Breast Cancer Clinical Trial

Official title:
Pilot Study of Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer

Clinical Trial Summary

The purpose of this study is to see how effective the combination of the two chemotherapy drugs (carboplatin and nab-paclitaxel) are when added to a third drug, pembrolizumab. Pembrolizumab is an investigational (experimental) drug that works by reinvigorating the immune system, allowing it to target and destroy cancer cells. Pembrolizumab is experimental because it is not approved by the Food and Drug Administration (FDA) for this type of breast cancer treatment.

Clinical Trial Description

Primary Objective - Determine overall response rate (ORR) in patients treated with CNP Secondary Objective(s) - Determine progression-free survival (PFS), and disease control rate (DCR) in patients treated with CNP. - Determine duration of response in patients treated with CNP. - Determine safety/tolerability of CNP. Correlative Endpoints - Identify pathologic and genomic correlates of response to CNP. Study design including dose escalation / cohorts This is prospective pilot clinical trial of CNP in up to 30 patients with mTNBC ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03121352
Study type Interventional
Source Case Comprehensive Cancer Center
Contact
Status Completed
Phase Phase 2
Start date May 19, 2017
Completion date May 23, 2022
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02158507 - Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer N/A
Completed NCT02555657 - Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) Phase 3
Completed NCT02834403 - L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients Phase 1/Phase 2
Active, not recruiting NCT03330847 - To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. Phase 2
Completed NCT03256344 - Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases Phase 1
Recruiting NCT04739670 - Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer Phase 2
Withdrawn NCT01936961 - Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors N/A
Completed NCT01238952 - Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer Phase 1
Completed NCT03577743 - Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer Phase 2
Completed NCT03411161 - S 81694 Plus Paclitaxel in Metastatic Breast Cancer Phase 1/Phase 2
Withdrawn NCT04149444 - A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer Phase 2
Withdrawn NCT05008510 - P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC . Phase 2
Completed NCT04111510 - Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer Phase 2
Terminated NCT03055312 - Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer Phase 3
Recruiting NCT03709446 - Leflunomide in Previously Treated Metastatic Triple Negative Cancers Phase 1/Phase 2